Company’s 36-month beta value is 0.92.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRDL is 77.72M, and currently, short sellers hold a 1.05% ratio of that floaft. The average trading volume of CRDL on January 31, 2025 was 367.09K shares.
CRDL) stock’s latest price update
The stock of Cardiol Therapeutics Inc (NASDAQ: CRDL) has increased by 8.40 when compared to last closing price of 1.31.Despite this, the company has seen a gain of 4.41% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) — PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
CRDL’s Market Performance
Cardiol Therapeutics Inc (CRDL) has seen a 4.41% rise in stock performance for the week, with a 8.40% gain in the past month and a -23.24% plunge in the past quarter. The volatility ratio for the week is 8.86%, and the volatility levels for the past 30 days are at 7.00% for CRDL. The simple moving average for the past 20 days is 7.82% for CRDL’s stock, with a -25.35% simple moving average for the past 200 days.
Analysts’ Opinion of CRDL
Many brokerage firms have already submitted their reports for CRDL stocks, with Rodman & Renshaw repeating the rating for CRDL by listing it as a “Buy.” The predicted price for CRDL in the upcoming period, according to Rodman & Renshaw is $7 based on the research report published on January 28, 2025 of the current year 2025.
ROTH MKM, on the other hand, stated in their research note that they expect to see CRDL reach a price target of $10. The rating they have provided for CRDL stocks is “Buy” according to the report published on June 26th, 2024.
H.C. Wainwright gave a rating of “Buy” to CRDL, setting the target price at $9 in the report published on April 22nd of the previous year.
CRDL Trading at 1.15% from the 50-Day Moving Average
After a stumble in the market that brought CRDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.49% of loss for the given period.
Volatility was left at 7.00%, however, over the last 30 days, the volatility rate increased by 8.86%, as shares surge +10.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.66% lower at present.
During the last 5 trading sessions, CRDL rose by +4.41%, which changed the moving average for the period of 200-days by -23.66% in comparison to the 20-day moving average, which settled at $1.3170. In addition, Cardiol Therapeutics Inc saw 10.94% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CRDL
The total capital return value is set at -2.29. Equity return is now at value -158.52, with -118.55 for asset returns.
Based on Cardiol Therapeutics Inc (CRDL), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -156.23.
Currently, EBITDA for the company is -29.59 million with net debt to EBITDA at 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.49.
Conclusion
In a nutshell, Cardiol Therapeutics Inc (CRDL) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
